✦ LIBER ✦

Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response

✍ Scribed by Martina Crysandt; Britta Neumann; Marco Das; Vera Engelbertz; Michael Bendel; Oliver Galm; Rainhardt Osieka; Edgar Jost

Book ID: 114794286
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 526 KB
Volume: 79
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2007.00955.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of rituximab and bortezomi

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

✍ Robert A. Baiocchi; Lapo Alinari; Mark E. Lustberg; Thomas S. Lin; Pierluigi Por 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 1 views

Phase II Study of Vincristine Sulfate Li

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

✍ Kaplan, Lawrence D.; Deitcher, Steven R.; Silverman, Jeffrey A.; Morgan, Gareth 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 203 KB

Phase II trial and prediction of respons

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial

✍ Delphine Rolland; Vincent Ribrag; Corinne Haioun; Herve Ghesquieres; Fabrice Jar 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 434 KB

Long-term results of the treatment of pa

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

✍ David J. Inwards; Paul A. S. Fishkin; David W. Hillman; David W. Brown; Stephen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). ## METHODS. Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial ther

The treatment of recurrent/refractory ch

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

✍ Clive S. Zent; Betsy R. LaPlant; Patrick B. Johnston; Timothy G. Call; Thomas M. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

Combined cyclophosphamide, vincristine,

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas : Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group

✍ Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Tr 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

## Abstract ## BACKGROUND. In patients with advanced‐stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades. ## METHODS. The German Low‐Grade Lymphom